Cargando…
How Should the Value Attributes of Novel Antibiotics Be Considered in Reimbursement Decision Making?
Antibiotics have revolutionized the treatment of bacterial infections. However, it is widely held that there is underinvestment in antibiotics research and development relative to the socially optimal level for a number of reasons. In this article, we discuss whether existing health technology asses...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935770/ https://www.ncbi.nlm.nih.gov/pubmed/31910245 http://dx.doi.org/10.1177/2381468319892237 |
_version_ | 1783483628024496128 |
---|---|
author | Morton, Alec Colson, Abigail Leporowski, Axel Trett, Anna Bhatti, Taimur Laxminarayan, Ramanan |
author_facet | Morton, Alec Colson, Abigail Leporowski, Axel Trett, Anna Bhatti, Taimur Laxminarayan, Ramanan |
author_sort | Morton, Alec |
collection | PubMed |
description | Antibiotics have revolutionized the treatment of bacterial infections. However, it is widely held that there is underinvestment in antibiotics research and development relative to the socially optimal level for a number of reasons. In this article, we discuss whether existing health technology assessment procedures recognize the full economic and societal value of new antibiotics to patients and society when making reimbursement decisions. We present three recommendations for modelling the unique attributes of value that are specific to novel antibiotics. We find, based on a review of the literature, that some of the value elements proposed by our framework have previously been discussed qualitatively by health technology assessment bodies when evaluating antibiotics, but are not yet formally captured via modelling. We present a worked example to show how it may be possible to capture these dimensions of value in a more quantitative manner. We conclude by answering the question of the title as follows: the unique attributes of novel antibiotics should be considered in reimbursement decision making, in a way that captures the full range of benefits these important technologies bring to patients, health care systems, and society. |
format | Online Article Text |
id | pubmed-6935770 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-69357702020-01-06 How Should the Value Attributes of Novel Antibiotics Be Considered in Reimbursement Decision Making? Morton, Alec Colson, Abigail Leporowski, Axel Trett, Anna Bhatti, Taimur Laxminarayan, Ramanan MDM Policy Pract Article Antibiotics have revolutionized the treatment of bacterial infections. However, it is widely held that there is underinvestment in antibiotics research and development relative to the socially optimal level for a number of reasons. In this article, we discuss whether existing health technology assessment procedures recognize the full economic and societal value of new antibiotics to patients and society when making reimbursement decisions. We present three recommendations for modelling the unique attributes of value that are specific to novel antibiotics. We find, based on a review of the literature, that some of the value elements proposed by our framework have previously been discussed qualitatively by health technology assessment bodies when evaluating antibiotics, but are not yet formally captured via modelling. We present a worked example to show how it may be possible to capture these dimensions of value in a more quantitative manner. We conclude by answering the question of the title as follows: the unique attributes of novel antibiotics should be considered in reimbursement decision making, in a way that captures the full range of benefits these important technologies bring to patients, health care systems, and society. SAGE Publications 2019-12-12 /pmc/articles/PMC6935770/ /pubmed/31910245 http://dx.doi.org/10.1177/2381468319892237 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Article Morton, Alec Colson, Abigail Leporowski, Axel Trett, Anna Bhatti, Taimur Laxminarayan, Ramanan How Should the Value Attributes of Novel Antibiotics Be Considered in Reimbursement Decision Making? |
title | How Should the Value Attributes of Novel Antibiotics Be Considered in
Reimbursement Decision Making? |
title_full | How Should the Value Attributes of Novel Antibiotics Be Considered in
Reimbursement Decision Making? |
title_fullStr | How Should the Value Attributes of Novel Antibiotics Be Considered in
Reimbursement Decision Making? |
title_full_unstemmed | How Should the Value Attributes of Novel Antibiotics Be Considered in
Reimbursement Decision Making? |
title_short | How Should the Value Attributes of Novel Antibiotics Be Considered in
Reimbursement Decision Making? |
title_sort | how should the value attributes of novel antibiotics be considered in
reimbursement decision making? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935770/ https://www.ncbi.nlm.nih.gov/pubmed/31910245 http://dx.doi.org/10.1177/2381468319892237 |
work_keys_str_mv | AT mortonalec howshouldthevalueattributesofnovelantibioticsbeconsideredinreimbursementdecisionmaking AT colsonabigail howshouldthevalueattributesofnovelantibioticsbeconsideredinreimbursementdecisionmaking AT leporowskiaxel howshouldthevalueattributesofnovelantibioticsbeconsideredinreimbursementdecisionmaking AT trettanna howshouldthevalueattributesofnovelantibioticsbeconsideredinreimbursementdecisionmaking AT bhattitaimur howshouldthevalueattributesofnovelantibioticsbeconsideredinreimbursementdecisionmaking AT laxminarayanramanan howshouldthevalueattributesofnovelantibioticsbeconsideredinreimbursementdecisionmaking |